Acurx Pharmaceuticals Inc (ACXP) Stock Price, Quote & News

Company Profile

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant st...

Industry: Biotechnology

Sector: Healthcare

Phone: 917 533 1469

Website: www.acurxpharma.com

Address:

259 Liberty Avenue, Staten Island, United States

GillyG Nov. 14 at 5:22 PM

$ACXP

0 · Reply

SquidGainz Nov. 13 at 11:41 PM

$ACXP $NIVF $FLGC $AQMS

0 · Reply

Bonso99 Nov. 13 at 5:24 PM

$ACXP🫡🫡🫡

0 · Reply

GillyG Nov. 13 at 4:59 PM

$ACXP 📈

0 · Reply

ProTraderColin Nov. 13 at 2:55 PM

$ACXP don’t worry these guys are still lining their pockets

1 · Reply

ChicagoJoe20 Nov. 13 at 2:07 PM

$ACXP they should have opted for ETH vs BTC as their reserve currency.

0 · Reply

Ueberschlaefer Nov. 13 at 3:06 AM

$ACXP watching this ticker drift back to under $1 again, even with a RS created low float. sad.

0 · Reply

Bonso99 Nov. 12 at 5:39 PM

$ACXP🫡🫡🫡🫡

1 · Reply

GillyG Nov. 12 at 1:01 PM

$ACXP About to explode📈

0 · Reply

Bonso99 Nov. 12 at 10:26 AM

$ACXP Acurx Pharmaceuticals (ACXP) owns patents in several major countries protecting its two antibiotic programs: 🧫 Ibezapolstat – for C. difficile infections. Patents in the U.S., Europe, Canada, Japan, and others. Main patents expire around 2030. 🧬 ACX-375C – a new class of antibiotics (DNA polymerase IIIC inhibitors). Patents in the U.S., Israel, Japan, India, and Australia. Protection extends to about 2039. In total, Acurx has around 11 granted patents worldwide, plus several pending applications in other countries. These patents secure ownership of their drug compounds and methods of use.

0 · Reply